These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28572590)

  • 1. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors.
    Zhu Y; Bassoff N; Reinshagen C; Bhere D; Nowicki MO; Lawler SE; Roux J; Shah K
    Sci Rep; 2017 Jun; 7(1):2602. PubMed ID: 28572590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
    Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
    Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis.
    Kim SL; Liu YC; Park YR; Seo SY; Kim SH; Kim IH; Lee SO; Lee ST; Kim DG; Kim SW
    Int J Oncol; 2015 Mar; 46(3):1121-30. PubMed ID: 25502339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
    Park KJ; Lee SH; Kim TI; Lee HW; Lee CH; Kim EH; Jang JY; Choi KS; Kwon MH; Kim YS
    Cancer Res; 2007 Aug; 67(15):7327-34. PubMed ID: 17671202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.
    Liu PC; Lu G; Deng Y; Wang CD; Su XW; Zhou JY; Chan TM; Hu X; Poon WS
    PLoS One; 2017; 12(1):e0171157. PubMed ID: 28135339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
    Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
    Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic applications of TRAIL receptor agonists in cancer and beyond.
    Amarante-Mendes GP; Griffith TS
    Pharmacol Ther; 2015 Nov; 155():117-31. PubMed ID: 26343199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.
    Jayasooriya RG; Choi YH; Hyun JW; Kim GY
    Environ Toxicol Pharmacol; 2014 Nov; 38(3):959-67. PubMed ID: 25461556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
    Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
    Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer.
    Moleirinho S; Kitamura Y; Borges PSGN; Auduong S; Kilic S; Deng D; Kanaya N; Kozono D; Zhou J; Gray JJ; Revai-Lechtich E; Zhu Y; Shah K
    Stem Cells Transl Med; 2023 Jul; 12(7):444-458. PubMed ID: 37311043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.